Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04874844
Status:
UNKNOWN
Last Update Posted:
2021-05-10
First Post:
2021-04-12
Brief Title:
JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
Sponsor:
Beijing Dongfang Biotech Co Ltd
Organization:
Beijing Dongfang Biotech Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2022-03-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-12
First Submit QC Date:
April 30 2021
Study First Post Date:
2021-05-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-05-07
Last Update Post Date:
2021-05-10
Last Update Post Date Type:
ACTUAL